Výsledky vyhledávání

Abstract 3900: The Safety and efficacy profile of a PD-L1 directed, Engineered Toxin Body, as a novel targeted direct-cell kill approach for the treatment of PD-L1 expressing cancers

Autor: Garrett L. Robinson, Jack P. Higgins, Brigitte Brieschke, Michaela Sousares, Hilario J. Ramos, Jensing Liu, Sara Le Mar, Veronica Partridge, Erin Willert, Joseph D. Dekker, Shaoyou Chu, Pablo A. Maceda, Aimee Iberg, Asis K. Sarkar

Publikováno v: Cancer Research. 79:3900-3900

Engineered Toxin Bodies (ETBs) are comprised of a deimmunized Shiga-like toxin subunit A (SLTA) genetically fused to an antibody-like targeting domain. The antibody targeting domain allows for specific targeting of cancer cells while the SLTA compone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f024970a13557d5364526260a0dc752
https://doi.org/10.1158/1538-7445.am2019-3900

Zobrazit plný text záznamu

Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma

Autor: Jack P. Higgins, Sanjay Patel, Garrett L. Robinson, Nibedita Chattopadhyay, Carole E. Harbison, Pu Shi, Jensing Liu, Dan Tavares, Anya Lublinsky, Haiqing Wang, Erin Willert, Sakeena Syed, John Newcomb, Janice Lee, Laura E. Packer, Yuhong Zhang

Publikováno v: Cancer Research. 79:2384-2384

Advances in the treatment of multiple myeloma have been driven by the development of new modalities, including proteasome inhibitors, immunomodulatory agents and monoclonal antibodies. TAK-169 is an engineered toxin body (ETB) comprising a proprietar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cfe09ec4379dc5be59ed5d3e5cd994ac
https://doi.org/10.1158/1538-7445.am2019-2384

Zobrazit plný text záznamu

Abstract 5769: Targeted Engineered Toxin Bodies provide a novel mechanism of action against HER2 positive cancers

Autor: Brigitte Brieschke, Hilario J. Ramos, Erin Willert, Sangeetha Rajagopalan, Jensing Liu, Garrett L. Robinson, Jack P. Higgins

Publikováno v: Cancer Research. 78:5769-5769

Molecular Templates develops highly potent, specific, next-generation immunotoxins that are proprietarily de-immunized to avoid both innate and adaptive immune recognition. These Engineered Toxin Bodies (ETBs) destroy cancer cells by enzymatic destru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2c8bf026be6182db0eacc263f653a50
https://doi.org/10.1158/1538-7445.am2018-5769

Zobrazit plný text záznamu

Abstract 2659: MT-4019: a de-immunized engineered toxin body targeting CD38 for multiple myeloma

Autor: Garrett L. Robinson, Brigitte Brieschke, Jennifer Erdman, Sangeetha Rajagopalan, Jane Neill, Rodney Flores, Jack P. Higgins, Jensing Liu, Erin Willert

Publikováno v: Cancer Research. 77:2659-2659

Molecular Templates is developing engineered toxin bodies (ETBs), potent recombinant immunotoxins that combine the specificity of an antibody fragment with the powerful direct cytotoxicity of the Shiga-like toxin A subunit (SLTA). ETBs can induce the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e7f27095cd4b7f840fc24c30b641646
https://doi.org/10.1158/1538-7445.am2017-2659

Zobrazit plný text záznamu

Abstract 1644: Combination of MT-3724 with sirolimus reduces anti-drug antibody response and prolongs drug exposure

Autor: Garrett L. Robinson, Erin Willert, Jensing Liu, Jack P. Higgins, Brigitte Brieschke, Sangeetha Rajagopalan

Publikováno v: Cancer Research. 77:1644-1644

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31c4cb6f978d52ceee1840fa81674c03
https://doi.org/10.1158/1538-7445.am2017-1644

Zobrazit plný text záznamu

Abstract 1483: MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin's lymphoma

Autor: Brigitte Brieschke, Rodney E. Flores-Lefranc, Jensing Liu, Erin Willert, Julia Foree, Garrett L. Robinson, Sangeetha Rajagopalan, Jack P. Higgins, William Null, Jennifer Erdman, Jane Neill

Publikováno v: Cancer Research. 76:1483-1483

Molecular Templates has developed engineered toxin bodies (ETBs), potent recombinant immunotoxins that combine the specificity of an antibody fragment with the powerful direct cytotoxicity of the Shiga-like toxin A subunit to specifically destroy tar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b1cb1536c71a2cf3b7a2b36032f1bf1
https://doi.org/10.1158/1538-7445.am2016-1483

Zobrazit plný text záznamu

Abstract A15: In vivo efficacy of a CD38-specific engineered toxin body

Autor: Jensing Liu, Jane Neill, Rodney Flores, Garrett L. Robinson, William Null, Erin Willert, Julia Foree, Jennifer Erdman, Brigitte Brieschke, Jack P. Higgins, Sangeetha Rajagopalan

Publikováno v: Clinical Cancer Research. 21:A15-A15

The cell surface glycoprotein CD38 is highly expressed on the surface of several B cell lineage cancers, such as the plasma cell malignancy multiple myeloma, some lymphomas and chronic lymphocytic leukemia (CLL), where it is a marker of unfavorable p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7bf359e46c1ffecbcb95e124ab77ebb6
https://doi.org/10.1158/1557-3265.hemmal14-a15

Zobrazit plný text záznamu

Abstract 2477: Engineered toxin bodies: A next-generation immunotoxin scaffold with novel immuno-oncology functionality

Autor: Garrett L. Robinson, William Null, Brigitte Brieschke, Jensing Liu, Erin Willert, Julia Foree, Jane Neill, Rodney Flores, Jack P. Higgins, Sangeetha Rajagopalan, Jennifer Erdman

Publikováno v: Cancer Research. 75:2477-2477

The potential of immunotoxins in oncology has been largely limited due to problems with immunogenicity as well as a limited number of appropriate targets. Advances in genetic engineering and molecular biology have been applied to overcome these limit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cc05ad769e19c50fc8d2390a0063cd5
https://doi.org/10.1158/1538-7445.am2015-2477

Zobrazit plný text záznamu

Abstract 647: CD20-specific Engineered Toxin Body demonstrates direct cell kill of multiple B-cell Non-Hodgkin's lymphoma types

Autor: Rodney Flores, Rachel Wirth, Jensing Liu, William Null, Jennifer Erdman, Kari Grant, Jack P. Higgins, Erin Willert, Brigitte Brieschke, Sangeetha Rajagopalan

Publikováno v: Cancer Research. 74:647-647

The B-cell membrane protein CD20 is expressed by both benign and neoplastic lymphocytes. It has been a superb target for immunotherapies targeting B-cell derived diseases. There are several anti-CD20 antibodies which have been developed for B-cell ly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5136f35a3adaf0a88bf599d14528d0d
https://doi.org/10.1158/1538-7445.am2014-647

Zobrazit plný text záznamu

Abstract 5477: Engineered toxin body demonstrating CD20-specific binding and cell kill in B-cell non-Hodgkin's lymphoma cells

Autor: Erin Willert, Rachel Wirth, William Null, Jensing Liu, Sangeetha Rajagopalan, Jennifer Erdman, Jack P. Higgins

Publikováno v: Cancer Research. 73:5477-5477

Non-Hodgkin's lymphoma (NHL) offers an attractive area for therapeutic biologics. The most successful example of this targeted approach is rituximab, which is approved for front and second line therapy of NHL. Rituximab targets the CD20 antigen expre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c614c4932af1d3d8fb7ffb3156c67fed
https://doi.org/10.1158/1538-7445.am2013-5477

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání